(DOCS) Doximity - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US26622P1075
Stock: Platform, Software, Solutions, Tools
Total Rating 35
Risk 91
Buy Signal -0.90
| Risk 5d forecast | |
|---|---|
| Volatility | 62.5% |
| Relative Tail Risk | -26.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.70 |
| Alpha | -88.74 |
| Character TTM | |
|---|---|
| Beta | 1.678 |
| Beta Downside | 2.019 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.42% |
| CAGR/Max DD | -0.06 |
EPS (Earnings per Share)
Revenue
Description: DOCS Doximity February 28, 2026
Doximity, Inc. (NYSE: DOCS) operates a U.S.-focused digital platform that equips physicians, nurse practitioners, physician assistants, medical students, pharma firms, and health systems with tools for collaboration, news aggregation, career management, on-call scheduling, documentation, and virtual patient visits.
Since its 2010 incorporation (formerly 3MD Communications), the company has grown its member base to over 2.2 million active clinicians, representing roughly 85 % of U.S. physicians, and generated FY 2025 revenue of $1.12 billion-a 27 % year-over-year increase driven by higher subscription uptake and expanding telehealth services.
Key sector dynamics supporting Doximity include sustained growth in healthcare IT spending (projected CAGR of 9 % through 2028) and the continued normalization of virtual care, which together boost demand for integrated digital workflow solutions.
Analysts note that Doximity’s adjusted EBITDA margin has risen to 21 % in FY 2025, reflecting improved monetization of its professional network and cost efficiencies from its cloud-native architecture.
For deeper quantitative analysis, you might explore the valuation metrics on ValueRay.
Headlines to watch out for
- Pharmaceutical advertising spend directly impacts Doximitys revenue growth
- Healthcare system adoption of telehealth services drives platform usage
- Physician engagement with digital tools influences subscription renewals
- Regulatory changes in telehealth reimbursement affect platform utilization
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 239.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 7.13 > 1.0 |
| NWC/Revenue: 132.3% < 20% (prev 163.0%; Δ -30.74% < -1%) |
| CFO/TA 0.27 > 3% & CFO 315.4m > Net Income 239.4m |
| Net Debt (-54.1m) to EBITDA (272.4m): -0.20 < 3 |
| Current Ratio: 6.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (199.2m) vs 12m ago -1.49% < -2% |
| Gross Margin: 89.75% > 18% (prev 0.90%; Δ 8885 % > 0.5%) |
| Asset Turnover: 54.76% > 50% (prev 46.94%; Δ 7.83% > 0%) |
| Interest Coverage Ratio: -13.84 > 6 (EBITDA TTM 272.4m / Interest Expense TTM -18.6m) |
Altman Z'' 6.46
| A: 0.73 (Total Current Assets 993.5m - Total Current Liabilities 149.8m) / Total Assets 1.16b |
| B: 0.02 (Retained Earnings 21.0m / Total Assets 1.16b) |
| C: 0.22 (EBIT TTM 257.7m / Avg Total Assets 1.16b) |
| D: 0.13 (Book Value of Equity 22.6m / Total Liabilities 177.7m) |
| Altman-Z'' Score: 6.46 = AAA |
Beneish M -2.97
| DSRI: 0.98 (Receivables 156.6m/137.5m, Revenue 637.8m/550.2m) |
| GMI: 1.00 (GM 89.75% / 90.19%) |
| AQI: 1.03 (AQ_t 0.12 / AQ_t-1 0.12) |
| SGI: 1.16 (Revenue 637.8m / 550.2m) |
| TATA: -0.07 (NI 239.4m - CFO 315.4m) / TA 1.16b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of DOCS shares?
As of March 09, 2026, the stock is trading at USD 25.34 with a total of 1,765,625 shares traded.
Over the past week, the price has changed by -1.40%, over one month by -7.85%, over three months by -44.53% and over the past year by -58.09%.
Over the past week, the price has changed by -1.40%, over one month by -7.85%, over three months by -44.53% and over the past year by -58.09%.
Is DOCS a buy, sell or hold?
Doximity has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold DOCS.
- StrongBuy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOCS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40 | 57.7% |
| Analysts Target Price | 40 | 57.7% |
DOCS Fundamental Data Overview March 05, 2026
P/E Trailing = 22.6639
P/E Forward = 16.2602
P/S = 7.9615
P/B = 4.8474
P/EG = 0.7072
Revenue TTM = 637.8m USD
EBIT TTM = 257.7m USD
EBITDA TTM = 272.4m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.35b USD (5.08b + Debt 10.7m - CCE 735.1m)
Interest Coverage Ratio = -13.84 (Ebit TTM 257.7m / Interest Expense TTM -18.6m)
EV/FCF = 13.97x (Enterprise Value 4.35b / FCF TTM 311.5m)
FCF Yield = 7.16% (FCF TTM 311.5m / Enterprise Value 4.35b)
FCF Margin = 48.85% (FCF TTM 311.5m / Revenue TTM 637.8m)
Net Margin = 37.54% (Net Income TTM 239.4m / Revenue TTM 637.8m)
Gross Margin = 89.75% ((Revenue TTM 637.8m - Cost of Revenue TTM 65.4m) / Revenue TTM)
Gross Margin QoQ = 89.89% (prev 90.25%)
Tobins Q-Ratio = 3.76 (Enterprise Value 4.35b / Total Assets 1.16b)
Interest Expense / Debt = 36.24% (Interest Expense 3.88m / Debt 10.7m)
Taxrate = 23.81% (19.2m / 80.8m)
NOPAT = 196.3m (EBIT 257.7m * (1 - 23.81%))
Current Ratio = 6.63 (Total Current Assets 993.5m / Total Current Liabilities 149.8m)
Debt / Equity = 0.01 (Debt 10.7m / totalStockholderEquity, last quarter 979.3m)
Debt / EBITDA = -0.20 (Net Debt -54.1m / EBITDA 272.4m)
Debt / FCF = -0.17 (Net Debt -54.1m / FCF TTM 311.5m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.56% (Net Income 239.4m / Total Assets 1.16b)
RoE = 22.89% (Net Income TTM 239.4m / Total Stockholder Equity 1.05b)
RoCE = 24.39% (EBIT 257.7m / Capital Employed (Equity 1.05b + L.T.Debt 10.7m))
RoIC = 18.77% (NOPAT 196.3m / Invested Capital 1.05b)
WACC = 12.13% (E(5.08b)/V(5.09b) * Re(12.10%) + D(10.7m)/V(5.09b) * Rd(36.24%) * (1-Tc(0.24)))
Discount Rate = 12.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF] Terminal Value 69.02% ; FCFF base≈279.8m ; Y1≈345.1m ; Y5≈587.7m
[DCF] Fair Price = 40.41 (EV 5.35b - Net Debt -54.1m = Equity 5.41b / Shares 133.8m; r=12.13% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 92.50 | EPS CAGR: 23.26% | SUE: 0.35 | # QB: 0
Revenue Correlation: 93.97 | Revenue CAGR: 19.91% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.34 | Chg7d=-0.001 | Chg30d=-0.029 | Revisions Net=-8 | Analysts=14
EPS next Year (2027-03-31): EPS=1.62 | Chg7d=-0.002 | Chg30d=-0.102 | Revisions Net=-13 | Growth EPS=+5.0% | Growth Revenue=+9.0%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.7% (Discount Rate 12.1% - Earnings Yield 4.4%)
[Growth] Growth Spread = -2.4% (Analyst 5.3% - Implied 7.7%)
P/E Forward = 16.2602
P/S = 7.9615
P/B = 4.8474
P/EG = 0.7072
Revenue TTM = 637.8m USD
EBIT TTM = 257.7m USD
EBITDA TTM = 272.4m USD
Long Term Debt = 10.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.08m USD (from shortTermDebt, last quarter)
Debt = 10.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.35b USD (5.08b + Debt 10.7m - CCE 735.1m)
Interest Coverage Ratio = -13.84 (Ebit TTM 257.7m / Interest Expense TTM -18.6m)
EV/FCF = 13.97x (Enterprise Value 4.35b / FCF TTM 311.5m)
FCF Yield = 7.16% (FCF TTM 311.5m / Enterprise Value 4.35b)
FCF Margin = 48.85% (FCF TTM 311.5m / Revenue TTM 637.8m)
Net Margin = 37.54% (Net Income TTM 239.4m / Revenue TTM 637.8m)
Gross Margin = 89.75% ((Revenue TTM 637.8m - Cost of Revenue TTM 65.4m) / Revenue TTM)
Gross Margin QoQ = 89.89% (prev 90.25%)
Tobins Q-Ratio = 3.76 (Enterprise Value 4.35b / Total Assets 1.16b)
Interest Expense / Debt = 36.24% (Interest Expense 3.88m / Debt 10.7m)
Taxrate = 23.81% (19.2m / 80.8m)
NOPAT = 196.3m (EBIT 257.7m * (1 - 23.81%))
Current Ratio = 6.63 (Total Current Assets 993.5m / Total Current Liabilities 149.8m)
Debt / Equity = 0.01 (Debt 10.7m / totalStockholderEquity, last quarter 979.3m)
Debt / EBITDA = -0.20 (Net Debt -54.1m / EBITDA 272.4m)
Debt / FCF = -0.17 (Net Debt -54.1m / FCF TTM 311.5m)
Total Stockholder Equity = 1.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.56% (Net Income 239.4m / Total Assets 1.16b)
RoE = 22.89% (Net Income TTM 239.4m / Total Stockholder Equity 1.05b)
RoCE = 24.39% (EBIT 257.7m / Capital Employed (Equity 1.05b + L.T.Debt 10.7m))
RoIC = 18.77% (NOPAT 196.3m / Invested Capital 1.05b)
WACC = 12.13% (E(5.08b)/V(5.09b) * Re(12.10%) + D(10.7m)/V(5.09b) * Rd(36.24%) * (1-Tc(0.24)))
Discount Rate = 12.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF] Terminal Value 69.02% ; FCFF base≈279.8m ; Y1≈345.1m ; Y5≈587.7m
[DCF] Fair Price = 40.41 (EV 5.35b - Net Debt -54.1m = Equity 5.41b / Shares 133.8m; r=12.13% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 92.50 | EPS CAGR: 23.26% | SUE: 0.35 | # QB: 0
Revenue Correlation: 93.97 | Revenue CAGR: 19.91% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.34 | Chg7d=-0.001 | Chg30d=-0.029 | Revisions Net=-8 | Analysts=14
EPS next Year (2027-03-31): EPS=1.62 | Chg7d=-0.002 | Chg30d=-0.102 | Revisions Net=-13 | Growth EPS=+5.0% | Growth Revenue=+9.0%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.7% (Discount Rate 12.1% - Earnings Yield 4.4%)
[Growth] Growth Spread = -2.4% (Analyst 5.3% - Implied 7.7%)